TRPML1 and Hair Growth: How a Lysosomal Iron “Safety Valve” May Stop DHT-Triggered Ferroptosis

Hispidulin’s most interesting hair-growth effect may not start with blood flow, hormone suppression or a conventional antioxidant pathway. It may start inside the lysosome: the acidic recycling compartment that stores, breaks down and redistributes cellular material.

A 2026 study proposes that the lysosomal channel TRPML1 acts as a safety valve for dermal papilla cells under androgen stress. By helping calcium and ferrous iron move out of lysosomes, TRPML1 may stop iron from accumulating in the wrong compartment, limit destructive lipid oxidation and prevent a form of regulated cell death called ferroptosis. Hispidulin activated this channel in the researchers’ experimental system and restored hair growth in a DHT-induced mouse model.

The mechanism is unusually specific and experimentally testable. It is also early-stage. No clinical trial has shown that hispidulin, a TRPML1 drug or any over-the-counter supplement can regrow hair in people.

What Is TRPML1—and Why Would a Hair Follicle Need It?

TRPML1, encoded by the MCOLN1 gene, is an ion channel embedded mainly in endosomal and lysosomal membranes. When it opens, it helps release calcium and metal ions from the lysosomal lumen into the cytoplasm. This signalling supports membrane trafficking, autophagy, organelle communication and cellular adaptation to stress.

TRPML1 is not merely a generic housekeeping protein. The new hair study reports that it is present in human and mouse follicles, particularly in the outer root sheath and dermal papilla. That location matters because dermal papilla cells sit at the base of the follicle and coordinate many of the signals that determine whether the follicle grows, miniaturizes or transitions out of anagen.

Think of the lysosome as both a recycling centre and a chemical store. Iron is essential, but poorly controlled ferrous iron can accelerate the formation of radicals that attack polyunsaturated lipids in cell membranes. TRPML1-mediated iron export may prevent the lysosome from becoming a concentrated source of that damage.

The DHT-to-Ferroptosis Chain Explained

Androgenetic alopecia is driven by androgen-sensitive follicular miniaturization. DHT changes gene expression and signalling within dermal papilla cells, weakening their capacity to support a large, long-lived anagen follicle. Oxidative stress has long been associated with this dysfunction, but “oxidative stress” alone does not identify exactly how a cell is injured or which intervention could stop it.

The 2026 study makes a more precise claim: DHT can push dermal papilla cells toward ferroptosis. Ferroptosis is distinct from apoptosis. It is an iron-dependent process in which lipid peroxides overwhelm membrane-protection systems. Once enough membrane lipid is oxidized, the cell can no longer maintain its structure or function.

This creates a plausible sequence:

1. DHT places androgen-sensitive dermal papilla cells under metabolic and oxidative stress.
2. Lysosomal iron handling becomes part of the stress response.
3. Excess redox-active iron helps drive lipid peroxidation.
4. Ferroptotic injury reduces dermal papilla cell survival, proliferation and hair-inductive capacity.
5. The follicle loses pro-growth support and is less able to maintain normal anagen architecture.

The important word is plausible. The investigators supported this pathway in cultured cells and a DHT-induced mouse model. They did not establish that ferroptosis is the dominant cause of ordinary human pattern hair loss.

How Hispidulin Appears to Activate the TRPML1 Safety Valve

The researchers first used structure-based molecular docking to identify natural compounds that might fit an agonist-binding pocket on TRPML1. Hispidulin emerged as a candidate. A cellular thermal shift assay supported direct target engagement, while calcium imaging showed channel activation.

That target-validation sequence is stronger than simply observing that a plant extract is “antioxidant.” It proposes a defined drug, receptor-like target and measurable ion-channel response.

When TRPML1 opened, lysosomal calcium and iron fluxes changed. The authors concluded that TRPML1-dependent lysosomal iron efflux reduced the iron-driven oxidative pressure that promotes ferroptosis. Dermal papilla cells then retained more of their proliferative and hair-inductive function.

Why the Inhibitor and Knockdown Experiments Matter

A mechanism becomes much more convincing when blocking it removes the benefit. That is what the study attempted to show.

Pharmacological inhibition of TRPML1 with ML-SI3 abolished hispidulin’s protective effects. Reducing TRPML1 expression with shRNA produced the same result. Separately, erastin—a ferroptosis inducer—reversed the recovery of dermal papilla proliferation and hair-inductive function.

These interventions support two connected conclusions: hispidulin’s effect depended on TRPML1, and suppression of ferroptosis was functionally important. They do not prove that the same pathway can be safely or effectively manipulated in a human scalp.

How Saving Dermal Papilla Cells Could Restart Anagen Signals

Dermal papilla cells are signalling organizers. Protecting them does not manufacture a hair shaft directly; it preserves the cellular niche that instructs neighbouring epithelial cells.

In the DHT-induced mice, oral hispidulin promoted visible hair regeneration and restored anagen-phase follicular architecture. The study also reported higher expression of Ctnnb1, which encodes beta-catenin, and Vegf, a vascular growth signal. Beta-catenin is central to hair-follicle growth and cycling, while VEGF can support the vascular environment around active follicles.

The most cautious interpretation is that preventing ferroptotic damage allowed the dermal papilla to resume a broader pro-anagen programme. It does not show that TRPML1 directly switches on every downstream growth factor, or that increasing VEGF alone explains regrowth.

Why TRPML1 Is More Than an “Antioxidant” Target

Many proposed hair-growth compounds are described vaguely as antioxidants. TRPML1 is more interesting because it connects several stress-control systems:

• Iron compartmentalization: moving ferrous iron out of lysosomes may reduce concentrated radical chemistry in that organelle.
• Calcium signalling: lysosomal calcium release communicates with the endoplasmic reticulum and other organelles.
• Autophagy and recycling: TRPML1 participates in lysosomal adaptation and clearance of damaged cellular material.
• Ferroptosis resistance: independent cancer-cell studies also show that loss or inhibition of TRPML1 can increase susceptibility to ferroptosis, although cancer biology cannot be directly translated to hair follicles.

This convergence makes TRPML1 a biologically coherent research target. It also creates safety complexity: a channel involved in iron, calcium and lysosomal homeostasis is unlikely to be something readers should manipulate casually with concentrated supplements.

What Is Proven, What Is Plausible and What Remains Unknown?

Shown in the 2026 experiments: hispidulin engaged and activated TRPML1 in the researchers’ assays; DHT-associated dermal papilla injury displayed ferroptosis-related features; blocking or knocking down TRPML1 removed hispidulin’s protection; inducing ferroptosis reversed restored cell function; and oral hispidulin improved hair growth in a DHT-induced mouse model.

Biologically plausible: better lysosomal iron handling may reduce lipid peroxidation, preserve dermal papilla viability and allow beta-catenin-, VEGF- and anagen-associated signalling to recover.

Unknown: whether the same pathway is a major driver of human androgenetic alopecia; the concentration required in human follicles; whether topical delivery can reach the dermal papilla; whether long-term systemic activation is safe; and whether hispidulin is the best therapeutic molecule rather than simply a useful laboratory lead.

Could You Activate TRPML1 for Hair Growth Now?

No clinically validated method currently exists. There is no approved TRPML1 hair-loss drug, no established topical hispidulin formulation and no human efficacy or dosing study for androgenetic alopecia.

Buying concentrated hispidulin or a botanical product that happens to contain it would not reproduce the study. Commercial products may differ in purity, dose and bioavailability, and oral dosing could expose many tissues—not just hair follicles—to the compound. The mouse study cannot establish a safe human dose.

Readers interested in the mechanism can act safely by tracking the research rather than self-experimenting:

• Look for replicated work in human follicle organ culture and scalp tissue.
• Watch for pharmacokinetic and toxicology studies showing whether useful concentrations reach the follicle.
• Give priority to registered human trials with a defined formulation, comparator and objective hair-count endpoints.
• For current hair loss, seek a proper diagnosis and discuss established options with a GP or dermatologist rather than substituting an untested flavonoid.

The Bottom Line

TRPML1 may function as a lysosomal iron-and-calcium safety valve that protects dermal papilla cells from DHT-associated ferroptosis. Hispidulin appears to open that valve in experimental systems, reducing lipid-peroxidation injury and allowing pro-anagen signalling to recover. The inhibitor, knockdown and ferroptosis-rescue experiments make this a compelling mechanism—not merely an antioxidant story.

But the evidence stops at cells and mice. Until researchers demonstrate safe follicular delivery and meaningful regrowth in controlled human trials, TRPML1 activation should be viewed as a promising drug-development direction, not a treatment readers can responsibly recreate at home.